Daniel Allen Gold Sells 625,783 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock in a transaction on Friday, June 26th. The shares were sold at an average price of $34.00, for a total transaction of $21,276,622.00. Following the completion of the transaction, the director directly owned 14,501,546 shares in the company, valued at $493,052,564. The trade was a 4.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40.
• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $35.03 on Thursday. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $35.90. The stock has a market capitalization of $25.20 billion, a price-to-earnings ratio of -58.38 and a beta of 1.10. The company has a 50-day simple moving average of $30.00 and a 200-day simple moving average of $27.11.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The firm had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter last year, the company posted ($0.29) earnings per share. As a group, research analysts forecast that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ROIV shares. Guggenheim boosted their target price on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Citigroup increased their price target on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, TD Cowen raised their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

Institutional Trading of Roivant Sciences

Several hedge funds have recently modified their holdings of ROIV. SBI Securities Co. Ltd. boosted its stake in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP raised its position in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares during the period. Kestra Advisory Services LLC acquired a new stake in Roivant Sciences in the fourth quarter valued at $47,000. Finally, Bessemer Group Inc. boosted its position in shares of Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after purchasing an additional 441 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.